Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Royalty income	$ 3,319	$ 1,208	$ 7,888	$ 3,155
Collaboration revenue	50,523	183	56,839	393
Other revenue	8	5	50	33
Total revenue	53,850	1,396	64,777	3,581
Operating expenses:
Research and development	9,827	7,048	26,964	20,255
General and administrative	7,220	4,572	18,637	14,424
Change in contingent consideration liability	600	(200)	1,400	900
Total operating expenses	17,647	11,420	47,001	35,579
Operating income (loss)	36,203	(10,024)	17,776	(31,998)
Other income:
Interest income	79	10	176	33
Total other income	79	10	176	33
Net income (loss)	36,282	(10,014)	17,952	(31,965)
Net income (loss) attributable to noncontrolling interests	(21)		(58)
Net income (loss) attributable to Progenics	$ 36,303	$ (10,014)	$ 18,010	$ (31,965)
Net income (loss) per share attributable to Progenics - basic (in dollars per share)	$ 0.52	$ (0.14)	$ 0.26	$ (0.46)
Weighted-average shares - basic (in shares)	70,013	69,705	69,970	69,663
Net income (loss) per share attributable to Progenics - diluted (in dollars per share)	$ 0.52	$ (0.14)	$ 0.26	$ (0.46)
Weighted-average shares - diluted (in shares)	70,297	69,705	70,006	69,663